Skip to content
10-Q

Quarterly Report

Y-mAbs Therapeutics, Inc.

0001558370-24-014950

← back to feed
Filed
Nov 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 1, 2024 44.79M sh
Shares Diluted Q3 2024 · Sep 30, 2024 44.63M sh
Shares Diluted Q3 2024 · Sep 30, 2024 44.15M sh
Shares Diluted Q3 2024 · Sep 30, 2023 43.62M sh
Shares Diluted Q3 2024 · Sep 30, 2023 43.65M sh
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$13.84M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$19.2M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $68.12M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $78.64M
Stockholders Equity Q3 2024 · Sep 30, 2024 $92.43M
Stockholders Equity Q3 2024 · Jun 30, 2024 $95.34M
Stockholders Equity Q3 2024 · Mar 31, 2024 $99.19M
Stockholders Equity Q3 2024 · Dec 31, 2023 $100.99M
Stockholders Equity Q3 2024 · Sep 30, 2023 $100.15M
Stockholders Equity Q3 2024 · Jun 30, 2023 $104.68M
Stockholders Equity Q3 2024 · Mar 31, 2023 $107.83M
Stockholders Equity Q3 2024 · Dec 31, 2022 $109.22M
Current Liabilities Q3 2024 · Sep 30, 2024 $25.29M
Current Liabilities Q3 2024 · Dec 31, 2023 $20.13M
Total Liabilities Q3 2024 · Sep 30, 2024 $28.49M
Total Liabilities Q3 2024 · Dec 31, 2023 $26.88M
Current Assets Q3 2024 · Sep 30, 2024 $99.06M
Current Assets Q3 2024 · Dec 31, 2023 $111.11M
Total Assets Q3 2024 · Sep 30, 2024 $120.92M
Total Assets Q3 2024 · Dec 31, 2023 $127.87M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.16
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.52
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.18
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.47
Eps Basic Q3 2024 · Sep 30, 2024 −$0.16
Eps Basic Q3 2024 · Sep 30, 2024 −$0.52
Eps Basic Q3 2024 · Sep 30, 2023 −$0.18
Eps Basic Q3 2024 · Sep 30, 2023 −$0.47
Sga Expense Q3 2024 · Sep 30, 2024 $13.61M
Sga Expense Q3 2024 · Sep 30, 2024 $42.27M
Sga Expense Q3 2024 · Sep 30, 2023 $10.2M
Sga Expense Q3 2024 · Sep 30, 2023 $33.72M
Rd Expense Q3 2024 · Sep 30, 2024 $11.17M
Rd Expense Q3 2024 · Sep 30, 2024 $36.78M
Rd Expense Q3 2024 · Sep 30, 2023 $15.36M
Rd Expense Q3 2024 · Sep 30, 2023 $40.83M
Net Income Q3 2024 · Sep 30, 2024 −$7M
Net Income Q3 2024 · Sep 30, 2024 −$22.88M
Net Income Q3 2024 · Jun 30, 2024 −$9.25M
Net Income Q3 2024 · Mar 31, 2024 −$6.63M
Net Income Q3 2024 · Sep 30, 2023 −$7.75M
Net Income Q3 2024 · Sep 30, 2023 −$20.44M
Net Income Q3 2024 · Jun 30, 2023 −$6.3M
Net Income Q3 2024 · Mar 31, 2023 −$6.39M
Operating Income Q3 2024 · Sep 30, 2024 −$8.57M
Operating Income Q3 2024 · Sep 30, 2024 −$25.27M
Operating Income Q3 2024 · Sep 30, 2023 −$7.75M
Operating Income Q3 2024 · Sep 30, 2023 −$22.47M
Cost Of Revenue Q3 2024 · Sep 30, 2024 $2.25M
Cost Of Revenue Q3 2024 · Sep 30, 2024 $7.36M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $2.6M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $9.33M
Revenue Q3 2024 · Sep 30, 2024 $18.46M
Revenue Q3 2024 · Sep 30, 2024 $61.19M
Revenue Q3 2024 · Sep 30, 2023 $20.45M
Revenue Q3 2024 · Sep 30, 2023 $61.46M